

To whom it may concern

**Management of clinical trials at Department of Oncology, Oslo University Hospital in relation to coronavirus**

The challenges arising with the extraordinary situation caused by coronavirus pandemic may affect the conduct of clinical trials at the Department of Oncology. Infection control and necessary reallocation of hospital resources/personnel may lead to deviations of protocol and local standard operating procedures.

In order to reduce the risk for subjects participating in clinical trials, the Department of Oncology has initiated the following actions:

- Start-up of new clinical trials is postponed
- Recruitment of new subjects into ongoing clinical trials is halted. This is the general rule, but individual exceptions can be made
- Efforts will be made to ensure that subjects included in clinical trials receive treatment and follow-up according to protocol. Patient safety will have the highest priority. Only mandatory protocol-defined examinations will be performed, unless considered important for patient care. Any protocol deviation due to the coronavirus situation will be documented

Monitoring visits will be postponed or replaced by remote monitoring.

Division of Cancer Medicine  
Department of Oncology



Date: 16.03.20

 Oslo  
universitetssykehus  
Reino Heikkilä  
Overlege / Seksjonsleder  
ID nr: 2112 205  
Avdeling for kreftbehandling